This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Asia Bio Partnering Forum

Event begins in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Marina Bay Sands Convention Center
April 24—25, 2024 | SingaporeApril 29—30, 2024 | Virtual

James Huang
Founder and Managing Partner at Panacea Venture
Speaker

Profile

James Huang is Founding Managing Partner of Panacea Healthcare Venture Capital. He has devoted his passion、diligence、intelligence and loyalty into life science and investment industry over 30 years. He is a successful entrepreneur、investor and an opinion leader in Venture Capital healthcare sector in China. Panacea Venture is focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide.

James Huang is also managing partner of Kleiner Perkins China. He joined the firm in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 15 investments in China since 2007.

Prior to that, James was a Managing Partner at Vivo Ventures, a Venture Capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).

James is a director at Kindstar Global (9960.HK)

James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

Agenda Sessions

  • Biotech IPO landscape in Asian markets: latest trends, predictions, and emerging ways to raise funds

    1:30pm

At this event